| Nemaura Medical (NASDAQ: NMRD) Reports Q2 Results |
| |
|
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, provided a business update for the second quarter ended September 30, 2019.
Key Quote: “This has been an exciting period for Nemaura as we officially commenced the commercial rollout plans for SugarBEAT® following our recent CE approval. We remain highly encouraged by the outlook for the business and look forward to providing further updates as we execute on our commercial strategy.” – Dr. Faz Chowdhurry, CEO
The Backstory: NMRD is a medical technology company commercializing SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) designed to help people with diabetes and pre-diabetics better manage their glucose levels by spending more time in range. Insulin users can adjunctively use SugarBEAT® when calibrated by a finger stick reading. SugarBEAT® consists of a daily, disposable adhesive skin-patch connected to a small form factor rechargeable transmitter, connected via Bluetooth to a specially designed mobile application, which displays glucose readings at five-minute intervals throughout the day.
Disclosure
Nemaura Medical (NMRD) is a client of RedChip Companies. NMRD agreed to pay RedChip a monthly cash fee of $5,000 for six months of investor awareness services. RedChip also received 20,000 shares of Rule 144 stock for services performed between December 2018 and May 2019.
|
|
| |
|
| Can-Fite (NYSE American: CANF) Obtains Patent for Treatment Of Osteoarthritis In Mammals |
| |
|
Can-Fite BioPharma (NYSE American: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced that its drug candidate Piclidenoson for the treatment of osteoarthritis in mammals has been granted Patent No. 10,265,337 from the U.S. Patent and Trademark Office with the title “Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment.”
Why It Matters: Piclidenoson, “a novel, first-in-class, A3 adenosine receptor agonist small molecule, orally bioavailable drug,” is said to offer safer and more effective oral treatment for canine osteoarthritis. It is also in Phase III trials for rheumatoid arthritis and psoriasis.
Key Quote: “As the number of companion animals increase and their role in family life becomes more prominent, the animal health market has shown robust growth. Piclidenoson may provide superior relief to companion animals for indications including canine osteoarthritis. While Can-Fite remains entirely focused on the development of Piclidenoson for rheumatoid arthritis and psoriasis indications, we do see an opportunity to out-license our drugs in the veterinary market.” - Dr. Pnina Fishman, CEO
The Backstory: CANF’s lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis. The Company’s liver cancer drug, Namodenoson, recently completed a Phase II trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and is in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. FDA. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction in preclinical studies and the Company is investigating additional compounds, targeting A3AR, for the treatment of sexual dysfunction. These drugs have an excellent safety profile with experience in over 1,000 patients in clinical studies to date.
Disclosure
Can-Fite Biopharma (CANF) is a client of RedChip Companies, Inc. CANF agreed to pay RedChip Companies, Inc. a cash fee of $5,000 monthly and 16,500 shares of CANF Rule 144 stock for 6 months of RedChip investor awareness services and consulting services.
|
|
| |
|
| Cyclo Therapeutics (OTCQB: CTDH) Signs Agreement with Leading CRO to Conduct Niemann-Pick Type C Trial |
| |
|
Cyclo Therapeutics (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, signed an agreement with Worldwide Clinical Trials (Worldwide), a leading Contract Research Organization (CRO), to conduct a pivotal trial that will evaluate the Company’s proprietary hydroxypropyl beta cyclodextrin, Trappsol® Cyclo™, administered by intravenous infusion to treat NPC.
Why It Matters: CTDH currently supports a Phase I trial in the United States, which recently completed enrollment (ClinicalTrials.gov NCT02939547); an Extension Protocol for the US study, which includes home-based infusions (NCT03893071); and a Phase I/II trial in Europe and Israel, which is nearing completion of enrollment (NCT02912793). The Company plans to share its design of the pivotal trial in scientific advice meetings with regulators in the US and Europe in first and second quarters of 2020, respectively. Enrollment of the trial is expected to commence shortly thereafter.
Key Quote: “We are very excited to work with Worldwide, an industry leader, on this critical clinical program. Our early phase trials are showing promising results, as we have reported publicly during the past year. Because of this, we are working quickly to present our pivotal trial design to regulators and hope to commence our pivotal trial in the early part of 2020. Worldwide will play a vital role as we build and execute the pivotal study.” -N. Scott Fine, Chairman and CEO
The Backstory: CTDH is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is in three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease (Clinical Trials.gov NCT02939547, NCT02912793 and NCT03893071), and in an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development.
Disclosure
Cyclo Therapeutics (OTCQB: CTDH) is a client of RedChip Companies, Inc. CTDH paid RedChip Companies, Inc. a fee of $30,000 per month for four months of RedChip investor awareness services and consulting services, beginning in August 2019.
|
|
| |
|
| SPI Energy (NASDAQ: SPI) Completes Acquisition of 4.4MW of Solar Projects in Greece |
| |
|
SPI Energy (NASDAQ: SPI), a global provider of green energy solutions with strategic investments in green-energy-enabled products and services, announced that SP Orange Power (Cyprus) Limited (“SP Orange”), a wholly owned subsidiary of the Company, has completed its acquisition of 100% of the equity interest of THERMI SUN S.A. (“Thermi Sun”), which owns 4.4 Megawatts ("MW") of photovoltaic (“PV”) projects in Greece. The PV projects at Thermi Sun have been connected to the Greek power grid since July 2012, and they are currently in operation.
Why It Matters: The Company’s 7.55-million-euro acquisition of Thermi Sun represents the last of three acquisitions completed under the terms of an agreement with THERMI TANEO Venture Capital Fund (“TTVCF”) that was executed in September 2017, as amended in 2019. SPI Energy, through SP Orange, acquired from TTVCF all of its equity interests in the three Greek companies (namely, THERMI SUN S.A, HELIOHRISI S.A., and HELIOSTIXIO S.A), which own a total of four PV plants with an aggregate capacity of 7.4MW in northern Greece that produce estimated revenue of 2.4 million euros annually.
Key Quote: “This acquisition represents another key milestone in our strategic plan regarding our global solar assets. As we continue to reorganize our business, our top priority is to seek out opportunities to optimize our global PV portfolio, improve our operating cash flows and enhance our operating margins.” – Xiaofeng Peng, Chairman and CEO
The Backstory: SPI is an established provider of photovoltaic solutions with global operations in key markets in Australia, Europe, Japan and the United States. The Company is leveraging its solar platform and expertise to make strategic investment in green industries with significant growth and earnings potential and/or green-energy-enabled products and services.
Disclosure
SPI Energy (SPI) is a client of RedChip Companies, Inc. SPI agreed to pay RedChip Companies, Inc. 25,000 shares of Rule 144 stock and a monthly cash fee of $6,500 for 12 months of RedChip investor awareness services and consulting services.
|
|
| |
|
| ChineseInvestors.com (OTCQB: CIIX) Provides Q2 Shareholder Update |
| |
|
ChineseInvestors.com (OTCQB: CIIX), an established financial news and investment portal and a leading industrial hemp retailer for the Chinese-speaking community, announced a second quarter update for FY 2020 from its Executive Team.
Why It Matters: Recent revenue growth has been largely attributable to the company’s China subsidiary, CBD Biotech. To improve the bottom line, management is refocusing and prioritizing its core business. The Company's main focus for its industrial hemp business in FY 2020 will be on its China operations where we have a robust product development pipeline.
Key Quote: “As we reflect on two decades of business, we have laid the foundation that has allowed us to make strategic investments and achieve rapid growth. Looking forward, we will concentrate on the rewarding opportunities that we have identified for ChineseInvestors.com and our valued shareholders, including the continued growth our core business, and continued diversification of our revenue streams through our industrial hemp-infused/CBD products in China and the U.S., which we believe will lead to increased revenues and improved profitability.” – Warren Wang, CEO
The Backstory: Founded in 1999, CIIX endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail, online and direct sales of hemp-based products and other health related products.
Disclosure
ChineseInvestors.com, Inc. (CIIX) is a client of RedChip Companies. CIIX pays RedChip a cash fee of $10,000 monthly for six (6) months of investor awareness services.
|
|
| |
|
| Catasys (NASDAQ: CATS) Schedules Q3 Conference Call for November 13, 2019 |
| |
|
Catasys (NASDAQ: CATS), a leading AI and technology-enabled healthcare company, today announced that the Company will be releasing financial results for its third quarter ended September 30, 2019, after the closing of the stock market on Wednesday, November 13, 2019.
The Company will also host a conference call/webcast that same day at 4:30 pm ET/1:30 pm PT.
Investors, analysts, employees and the general public are invited to listen to the conference call via:
Conference Call:
877-705-2969 (domestic) or 201-689-8868 (international)
The Backstory: CATS is a leading AI and technology-enabled healthcare company whose mission is to help improve the health and save the lives of as many people as possible. Its Catasys PRETM (Predict-Recommend-Engage) platform predicts people whose chronic disease will improve with behavior change, recommends effective care pathways that people are willing to follow, and engages people who aren’t getting the care they need. By combining predictive analytics with human engagement, Catasys delivers improved member health and validated outcomes and savings to healthcare payers.
Disclosure
Catasys (CATS) is a client of RedChip Companies, Inc. CATS agreed to pay RedChip Companies, Inc. a $5,000 monthly cash fee for RedChip investor awareness services and consulting services.
|
|
| |
|
| Digital Ally (NASDAQ: DGLY) Schedules Q3 Conference Call for November 14, 2019 |
| |
|
Digital Ally (NASDAQ: DGLY), which develops, manufactures and markets advanced video recording products for law enforcement, emergency management, fleet safety and security, today announces that it will host an investor conference call on Thursday, November 14 at 11:15 a.m. EDT to discuss its operating results for the third quarter ended September 30, 2019, the status of its patent infringement litigation against Axon Enterprise, Inc. (“Axon,” formerly known as TASER International, Inc.) and insight into fourth quarter 2019 and 2020. The Company will release its operating results for the third quarter of 2019 prior to the conference call.
Investor Conference Call
Shareholders and other interested parties may participate in the conference call by dialing (844) 761-0863 and entering conference ID #3162567 a few minutes before 11:15 a.m. EDT on Thursday, November 14, 2019.
The Backstory: DGLY, headquartered in Lenexa, KS, specializes in the design and manufacturing of the highest quality video recording equipment and video analytic software. Digital Ally pushes the boundaries of technology in industries such as law enforcement, emergency management, fleet safety and security. Digital Ally’s complete product solutions include in-car and body cameras, cloud and local management software, and automatic recording technology. Digital Ally products are sold by domestic direct sales representatives and international distributors worldwide.
Disclosure
Digital Ally, Inc. (DGLY) is a client of RedChip Companies, Inc. DGLY agreed to pay RedChip Companies, Inc., a $7,500 monthly cash fee for RedChip investor awareness services.
|
|
| |
|
| |
| Quote of the Week |
| |
"An investment in knowledge pays the best interest"
-Benjamin Franklin |
|
|
|
|
|
|
|
| About RedChip |
| |
| RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. |
| |
| RedChip Disclosure |
| |
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and view RedChip’s Disclosures. |
|
| |
|
|
| |
|
|
Copyright © 2019 RedChip Companies, Inc. All Rights Reserved.
You are receiving this message because this email address has signed up to receive News Alerts.
|
|
|
|
|
